Resources with keywords: zika virus
CDC ArboNET and Florida health bulletins confirmed ongoing domestic Zika surveillance, recording 5 travel-associated cases nationally with zero local vector transmission in 2026. Public health advisories emphasize aggressive differential testing in febrile patients. Diagnostic laboratories are alerted to extensive serological IgM cross-reactivity between Zika and Dengue viruses, which complicates antibody confirmation. Clinicians must order molecular RT-PCR on serum and urine to assess fetal microcephaly risks. Diagnostic specimen processing must be performed within certified Class II Biosafety Cabinets under BSL-2 containment.
Ten Zika virus disease cases were detected in and around Dhaka, Bangladesh, during September–December 2024: Most were initially suspected to be dengue or chikungunya and were identified incidentally through a multiplex reverse transcription–polymerase chain reaction assay.
ATCC is a repository of biological materials. This is a sample from Trinidad.
Worldwide, there have been no reports of transmission of OROV by transfusion of blood or blood components. FDA will continue to monitor cases of OROV disease in the U.S. and worldwide and will issue updated information as it becomes available.
From FDA’s Release: Ixchiq is administered as a single dose by injection into the muscle. It contains a live, weakened version of the chikungunya virus and may cause symptoms in the vaccine recipient similar to those experienced by people who have chikungunya disease.
Reference document on Chikungunya Virus
This chapter includes information on the agent, transmission, diagnosis, treatment, prevention, epidemiology
